

CERTIFICATE

Survey of 30 August 2024

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Autoimmune Diseases 13 - Antiphospholipid Syndrome (275):

Validity 24 months:

anti-Cardiolipin (IgG)

anti-Cardiolipin (IgM)

anti- β 2-Glycoprotein (IgG)

anti- β 2-Glycoprotein (IgM)

(R) analysis is subject to the RiliBÄK

Customer:

10049579

Doc. MUDr., CSc. Tomas Kvasnicka

Vseobecná fakultní nemocnice v Praze

Trombotické centrum - Lab. dedic. vad hemostazy

Karlovo náměstí 554/32

128 08 Praha

Düsseldorf, 23 October 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. rer. nat. Martin Blüthner
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 30 August 2024

You have participated in the External Quality Assessment with the following analysis


Autoimmune Diseases 13 - Antiphospholipid Syndrome (275):

anti-Cardiolipin (IgG)
anti-Cardiolipin (IgM)
anti- β 2-Glycoprotein (IgG)
anti- β 2-Glycoprotein (IgM)

(R) analysis is subject to the RiliBÄK

Customer:
10049579
Doc. MUDr., CSc. Tomas Kvasnicka
Vseobecna fakultni nemocnice v Praze
Tromboticke centrum - Lab. dedic. vad hemostazy
Karlovo namesti 554/32
128 08 Praha

Düsseldorf, 23 October 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. rer. nat. Martin Blüthner
(Adviser)